| Literature DB >> 30143868 |
Heinz Läubli1,2,3, Stefan Dirnhofer4,5, Alfred Zippelius6,7,4.
Abstract
Recent progress in the understanding of immune responses to cancer and how tumor cells evade immune control have led to the successful introduction of cancer immunotherapy, in particular immune checkpoint inhibitors (ICI). Treatment of cancer patients with immunotherapy such as ICIs has led to new challenges, including starting and stopping rules for immunotherapy, the management of immune-related adverse events, and logistic issues for the production of cellular therapies and viral delivery vectors. These challenges are not disease- or organ-specific and several potential biomarkers to predict response to ICI are under investigation. We installed an interdisciplinary discussion platform for managing patient-specific challenges associated with cancer immunotherapy in our institution. Here, we describe an immune tumor board for the management of cancer patients treated with immunotherapy and provide an outlook on how such a platform could be potentially used in the future to discuss rational and personalized combination therapies, and how to improve the management of side effects occurring under immunotherapy.Entities:
Keywords: CTLA-4; Cellular therapies; Immune checkpoint inhibitors; Immune-related adverse events; PD-1
Mesh：
Year: 2018 PMID： 30143868 DOI： 10.1007/s00428-018-2435-9
Source DB: PubMed Journal: Virchows Arch ISSN： 0945-6317 Impact factor: 4.064